Therapeutic Role of MSC-Secretome in Type 2 Diabetic Models: Correlation between Improved HOMA-IR and Attenuated Pancreatic-Hepatic Structural Alterations
Observational analysis finds MSC-secretome improves HOMA-IR and mitigates pancreatic and hepatic damage in T2DM models, indicating potential as a novel therapy.
Key Points
Treatment with MSC-secretome markedly reduced HOMA-IR and insulin levels, suggesting improved insulin sensitivity.
Histological analyses revealed significant pancreatic degeneration in untreated T2DM rats, confirming the severity of insulin resistance.
Hypoxic MSC-secretome administration restored lobular architecture and reduced lipid accumulation in liver tissues of treated rats.
The reparative effects of MSC-secretome are attributed to its bioactive components that regulate oxidative stress and inflammation.